Literatur

• Literatur

• 1 Willnow TE, Nykjaer A. Pathways for kidney-specific uptake of the steroid hormone 25-hydroxyvitamin d3. Curr Opin Lipidol 2002; 13: 255-260.
• 2 Levin A, Bakris GL, Molitch M. et al. Prevalence of abnormal serum vitamin d, pth, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
• 3 Nykjaer A, Dragun D, Walther D. et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(oh) vitamin d3. Cell 1999; 96: 507-515.
• 4 Liu W, Yu WR, Carling T. et al. Regulation of gp330/megalin expression by vitamins a and d. Eur J Clin Invest 1998; 28: 100-107.
• 5 de Boer IH, Ioannou GN, Kestenbaum B. et al. 25-hydroxyvitamin d levels and albuminuria in the third national health and nutrition examination survey (nhanes iii). Am J Kidney Dis 2007; 50: 69-77.
• 6 Gutierrez O, Isakova T, Rhee E. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
• 7 Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin d metabolism in vivo and suppresses 25-hydroxyvitamin d-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293: F1577-F1583.
• 8 Torres PA, De Brauwere DP. Three feedback loops precisely regulating serum phosphate concentration. Kidney Int 2011; 80: 443-445.
• 9 Szabo A, Ritz E, Schmidt-Gayk H, Reichel H. Abnormal expression and regulation of vitamin d receptor in experimental uremia. Nephron 1996; 73: 619-628.
• 10 Gallieni M, Kamimura S, Ahmed A. et al. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 1995; 268: F746-F753.
• 11 Melamed ML, Astor B, Michos ED. et al. 25-hydroxyvitamin d levels, race, and the progression of kidney disease. J Am Soc Nephrol 2009; 20: 2631-2639.
• 12 Wolf M, Shah A, Gutierrez O. et al. Vitamin d levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
• 13 Ali FN, Arguelles LM, Langman CB, Price HE. Vitamin d deficiency in children with chronic kidney disease: Uncovering an epidemic. Pediatrics 2009; 123: 791-796.
• 14 Querfeld U, Mak RH. Vitamin d deficiency and toxicity in chronic kidney disease: In search of the therapeutic window. Pediatr Nephrol 2010; 25: 2413-2430.
• 15 Covic A, Kothawala P, Bernal M. et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506-1523.
• 16 Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008; 21: 300-307.
• 17 Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119.
• 18 Mehrotra R, Kermah DA, Salusky IB. et al. Chronic kidney disease, hypovitaminosis d, and mortality in the united states. Kidney Int 2009; 76: 977-983.
• 19 Pilz S, Tomaschitz A, Friedl C. et al. Vitamin d status and mortality in chronic kidney disease. Nephrol Dial Transplant 2011; 26 (11) 3603-3609.
• 20 Goldsmith DJ, Covic A, Fouque D. et al. Endorsement of the kidney disease improving global outcomes (kdigo) chronic kidney disease-mineral and bone disorder (ckd-mbd) guidelines: A european renal best practice (erbp) commentary statement. Nephrol Dial Transplant 2010; 25: 3823-3831.
• 21 Silver J, Naveh-Many T, Mayer H. et al. Regulation by vitamin d metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986; 78: 1296-1301.
• 22 Briese S, Wiesner S, Will JC. et al. Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin d therapy. Nephrol Dial Transplant 2006; 21: 1906-1914.
• 23 Oh J, Wunsch R, Turzer M. et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106: 100-105.
• 24 Zebger-Gong H, Muller D, Diercke M. et al. 1,25-dihydroxyvitamin d3 – induced aortic calcifications in experimental uremia: Upregulation of osteoblast markers, calcium-transporting proteins and osterix. J Hypertens; accepted for publication.
• 25 Ketteler M, Rothe H, Kruger T. et al. Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol 2011; 07: 509-516.
• 26 Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453-1464.
• 27 Blacher J, Guerin AP, Pannier B. et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
• 28 Shroff R, Egerton M, Bridel M. et al. A bimodal association of vitamin d levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008; 19: 1239-1246.
• 29 Matias PJ, Jorge C, Ferreira C. et al. Cholecalciferol supplementation in hemodialysis patients: Effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 05: 905-911.
• 30 Kandula P, Dobre M, Schold JD. et al. Vitamin d supplementation in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 06: 50-62.
• 31 Kooienga L, Fried L, Scragg R. et al. The effect of combined calcium and vitamin d3 supplementation on serum intact parathyroid hormone in moderate ckd. Am J Kidney Dis 2009; 53: 408-416.
• 32 Palmer SC, McGregor DO, Macaskill P. et al. Metaanalysis: Vitamin d compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840-853.
• 33 Shoji T, Shinohara K, Kimoto E. et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin d3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184.
• 34 Shoben AB, Rudser KD, de Boer IH. et al. Association of oral calcitriol with improved survival in nondialyzed ckd. J Am Soc Nephrol 2008; 19: 1613-1619.
• 35 Teng M, Wolf M, Lowrie E. et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
• 36 Sprague SM, Llach F, Amdahl M. et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490.
• 37 Block GA, Zaun D, Smits G. et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78: 578-589.
• 38 Moe SM, Chertow GM, Coburn JW. et al. Achieving nkf-k/doqi bone metabolism and disease treatment goals with cinacalcet hcl. Kidney Int 2005; 67: 760-771.
• 39 Raggi P, Chertow GM, Torres PU. et al. The advance study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin d on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-1339.
• 40 Chertow GM, Pupim LB, Block GA. et al. Evaluation of cinacalcet therapy to lower cardiovascular events (evolve): Rationale and design overview. Clin J Am Soc Nephrol 2007; 02: 898-905.